Merav Leiba

Phase I Safety and Pharmacokinetic Study of CT-011, a Humanized Antibody Interacting with PD-1, in Patients with Advanced Hematologic Malignancies

Raanan Berger, Rinat Rotem‐Yehudar, Gideon Slama et al. · Clinical Cancer Research · 2008 · 692 citations

Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu

Yu‐Tzu Tai, Myles Dillon, Weihua Song et al. · Blood · 2007 · 467 citations · Full text

Daratumumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: extended follow-up of POLLUX, a randomized, open-label, phase 3 study

Nizar J. Bahlis, Meletios Α. Dimopoulos, Darrell White et al. · Leukemia · 2020 · 231 citations · Full text

Daratumumab plus lenalidomide and dexamethasone <i>versus</i> lenalidomide and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of POLLUX

Meletios Α. Dimopoulos, Jesús F. San Miguel, Andrew R. Belch et al. · Haematologica · 2018 · 207 citations · Full text

Multiple myeloma cells recruit tumor-supportive macrophages through the CXCR4/CXCL12 axis and promote their polarization toward the M2 phenotype

Katia Beider, Hanna Bitner, Merav Leiba et al. · Oncotarget · 2014 · 158 citations · Full text